Connect Biopharma Files March 2025 6-K Report
Ticker: CNTB · Form: 6-K · Filed: Mar 28, 2025 · CIK: 1835268
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Connect Biopharma filed its March 2025 6-K, standard reporting for foreign issuers.
AI Summary
Connect Biopharma Holdings Ltd. filed a Form 6-K on March 28, 2025, reporting information for the month of March 2025. The company is a foreign private issuer and is subject to reporting requirements under the Securities Exchange Act of 1934. Its principal executive offices are located in San Diego, California.
Why It Matters
This filing provides routine updates for Connect Biopharma Holdings Ltd. as a foreign private issuer, which is important for investors tracking the company's compliance and reporting status.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- Connect Biopharma Holdings Ltd (company) — Filer of the 6-K report
- San Diego, California (location) — Location of principal executive offices
FAQ
What type of company is Connect Biopharma Holdings Ltd. according to this filing?
Connect Biopharma Holdings Ltd. is identified as a foreign private issuer.
What is the filing date of this Form 6-K?
The filing date is March 28, 2025.
What is the Commission File Number for Connect Biopharma Holdings Ltd.?
The Commission File Number is 001-40212.
Where are Connect Biopharma Holdings Ltd.'s principal executive offices located?
The principal executive offices are located at 3580 Carmel Mountain Road, Suite 200, San Diego, California, USA.
Under which act is this report filed?
This report is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 28, 2025 regarding Connect Biopharma Holdings Ltd (CNTB).